<DOC>
	<DOCNO>NCT02506114</DOCNO>
	<brief_summary>This multicentered , open label , randomize phase II trial PROSTVAC ipilimumab combination PROSTVAC ipilimumab neoadjuvant therapy patient localized PC . Eligible patient randomize PROSTVAC monotherapy ( Arm A ) , ipilimumab monotherapy ( Arm B ) , combination therapy PROSTVAC ipilimumab ( Arm C ) , prior RP . In arm A C , PROSTVAC-V administer subcutaneously primary vaccine Day 1 , follow 2 week later series 2 PROSTVAC-F subcutaneous administration , give 3 week apart . In arm B C , ipilimumab administer twice , dose 3mg/kg , 3 week apart . In combination arm , ipilimumab administration coincide PROSTVAC-F administration . In arm B , ipilimumab begin Day 1 . In three arm , RP occur 21 day , three week , follow final treatment administration PROSTVAC ipilimumab . No therapy administer study follow RP .</brief_summary>
	<brief_title>Neoadjuvant PROSTVAC-VF With Without Ipilimumab Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must histologically confirm adenocarcinoma prostate without previous therapy PC . Treatmentnaïve AND Undergoing RP initial , locally definitive therapy PC AND Eligible RP 3 month timeframe AND Consentable RP Subject 's prostate tissue biopsy , minimum 6 core , available appropriate IHC evaluation , subject consent provide tissue study endpoint analysis . Age ≥ 18 year Subject Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Subject adequate organ function , define : White blood cell ( WBC ) count ≥ 3,000/mcL Absolute neutrophil count ( ANC ) ≥ 1,500/mcL Platelet count ≥ 100,000/mcL Hemoglobin ( Hgb ) ≥ 10.0 g/dL Creatinine ≤ 1.5x institutional ULN Total bilirubin ≤ 1.5 x institutional ULN Alanine aminotransferase ( ALT ) ≤ 1.5 x institutional ULN Aspartate aminotransferase ( AST ) ≤ 1.5 x institutional ULN PT/INR , PTT within institutional ULN No known history human immunodeficiency virus ( HIV ) 1 2 , human Tcell lymphotropic virus ( HTLV ) I/II , Hepatitis B C. Ability understand write informed consent document , willingness sign . Subject 's biopsy specimen reveals neuroendocrine small cell feature . Subject evidence metastatic disease ( preoperative staging undertaken per urologic standard care ) . Subject prior use hormone , include luteinizing hormonereleasing hormone ( LHRH ) agonists , ketoconazole , antiandrogens ( bicalutamide , flutamide , nilutamide ) , 5αreductase inhibitor time prior study screen . Subject prior use anticancer treatment product , PCSPES ( PCx product : PCHOPE , PCCARE , PCPLUS , etc ) . Subject receive prior radiation therapy chemotherapy prostate cancer . Chronic administration ( defined daily every day continuous use &gt; 14 day ) systemic corticosteroid within 28 day first plan dose PROSTVACV/F . Use inhaled steroid , nasal spray , topical cream small body area allow . Active atopic dermatitis skin condition disrupts epidermis Inflammatory eye disease require steroid treatment History prior solid organ bone marrow transplant Previous history hypersensitivity egg allergy untoward reaction prior vaccinia ( smallpox ) vaccination . Splenectomy Subject , subject 's close household contact ( define share housing close physical contact ) follow condition screen and/or treatment period : active history atopic dermatitis , eczema eczematoid skin disorder disrupt epidermis acute , chronic exfoliative skin condition ( e.g. , burn , impetigo , varicella zoster , severe acne open rash wound ) condition resolve pregnant nursing immunodeficient immunosuppressed ( disease therapy ) , include HIV infection Subject 's close household contact include child less age three History , active autoimmune disease ( e.g. , autoimmune neutropenia , thrombocytopenia , hemolytic anemia , systemic lupus erythematosis , Sjogren´s syndrome , scleroderma , myasthenia gravis , Goodpasture´s syndrome , Addison´s disease , Hashimotos´s thyroiditis , Graves disease ) determine treat medical oncologist. '' . Persons vitiligo exclude . Diabetics exclude condition well control Hemoglobin A1C &lt; 7.0 No evidence endorgan damage due diabetes , diabetic retinopathy , nephropathy , neuropathy Persons hypothyroidism exclude condition well control , condition due nonautoimmune etiology . Subject receive treatment investigational immunotherapy within 2 year prior study screen receive treatment investigational product within 28 day prior study screen . Subject participate previous study involve PROSTVACV/F , SipuleucelT ipilimumab , regardless whether subject receive PROSTVACV/F , SipuleucelT ipilimumab . Subject history allergic reaction attribute compound similar chemical biologic composition PROSTVACV/F ipilimumab . Subject history stage III great cancer , exclude prostate cancer . Subjects history basal squamous cell skin cancer allow , provide subject adequately treat diseasefree time study screen . Subjects history stage I II cancer must adequately treated diseasefree ≥ 3 year prior study screen . Subject uncontrolled , concurrent illness include , limited following : ongoing active infection ( bacterial , viral , fungal ) , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , stroke myocardial infarction within 6 month , psychiatric illness would limit compliance study requirement . Subject require medical intervention ( ) condition ( ) , Investigator 's opinion , 1 ) make administration PROSTVACV/F ipilimumab hazardous , 2 ) obscure interpretation AEs , 3 ) compromise adherence study requirement , 4 ) otherwise compromise study 's objective . Subject highrisk feature ( e.g. , base Gleason score , PSA , clinical stage , % positive biopsy ) , treat physician feel subject undergo radical prostatectomy sooner plan within protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>prostate</keyword>
</DOC>